Last reviewed · How we verify
Paxlovid (Copackaged) (paxlovid)
Paxlovid works by inhibiting the activity of the SARS-CoV-2 protease enzyme, which is essential for the virus's replication.
Paxlovid (Copackaged) is a small molecule modality developed by Pfizer, Inc. for the treatment of COVID-19. It was FDA approved in 2023 and is currently owned by Pfizer, Inc. The commercial status of Paxlovid is patented, and it is used to treat COVID-19. Key safety considerations include potential interactions with other medications and monitoring for liver enzyme elevations. As a COVID-19 treatment, Paxlovid has become a crucial tool in managing the pandemic.
At a glance
| Generic name | paxlovid |
|---|---|
| Sponsor | Pfizer |
| Therapeutic area | Immunology |
| Phase | discontinued |
| First approval | 2023 |
Mechanism of action
Imagine your body's cells are under attack by the COVID-19 virus. Paxlovid helps by blocking a specific enzyme that the virus needs to multiply and spread. This allows your immune system to fight off the infection more effectively.
Approved indications
- COVID-19
Common side effects
- Drug interaction
- Acute kidney injury
- Toxicity to various agents
Key clinical trials
- RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
- COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II) (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
- A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
- Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 (PHASE2)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1,PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paxlovid (Copackaged) CI brief — competitive landscape report
- Paxlovid (Copackaged) updates RSS · CI watch RSS
- Pfizer portfolio CI